Pharmaron Beijing (300759.SZ) released a preliminary announcement, forecasting a net profit of 1.729 billion to 1.857 billion yuan for the year, with a year-on-year increase of 8% to 16%.

Pharmaron Beijing (300759.SZ) disclosed its annual performance forecast for 2024, with the company expecting a net profit attributable to shareholders of listed companies of 17.29 billion to 18.57 billion yuan, an increase of 8% to 16% year-on-year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses is expected to be 10.75 billion to 11.51 billion yuan, a year-on-year decrease of 24% to 29%.